Inclusion Criteria:

- Histologically-confirmed small cell lung cancer.

- Limited stage disease (

- ECOG performance status 0 or 1.

- No previous treatment with chemotherapy, radiation therapy, or biologic agents.

- Measurable disease

- Adequate bone marrow, liver, kidney function

- Patients must be able to understand the nature of this study and give written
consent.

Exclusion Criteria:

- Age < 18 years

- History of a prior malignancy within three years with the exception of skin cancer
(excluding melanoma), cervical carcinoma in situ, in situ breast carcinoma, or early
stage prostate cancer.

- Women who are pregnant or lactating are ineligible. Men and women of childbearing
potential are required to use adequate contraception during this study.

- History or physical exam evidence of CNS disease (eg seizures not controlled with
standard medical therapy, history of stroke)

- Active infection requiring parenteral antibiotics

- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
prior to Day 0, or fine needle aspiration within 7 days of beginning bevacizumab or
anticipation of need for major surgical procedure during the course of the study.

- Full-dose oral or parenteral anticoagulation must be on a stable dosing schedule
prior to enrollment.

- Proteinuria

- Serious nonhealing wound, ulcer, or bone fracture

- Evidence of bleeding diathesis or coagulopathy

- Prior hemoptysis.

- History of acute myocardial infarction or stroke within 6 months

- Uncontrolled hypertension (> 150/100), unstable angina, New York Heart Association
grade II or greater CHF, serious cardiac arrhythmia requiring medication, or grade II
or greater peripheral vascular disease.

- Received other investigational drugs within 28 days

- PEG, G-tubes, or other percutaneous drains/tubes

- History of any other disease, metabolic dysfunction, physical examination finding, or
clinical laboratory finding giving reasonable suspicion of a disease or condition
that contraindicates use of an investigational drug or that might affect
interpretation of the results of the study or place the subject at high risk for
treatment complications

- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal
abscess within the previous 6 months